You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Claims for Patent: 12,213,964

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,213,964

Title:	Isoxazoline parasiticide formulations
Abstract:	Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Inventor(s):	Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
Assignee:	Tarsus Pharmaceuticals Inc
Application Number:	US18/325,910
Patent Claims:	1. An ophthalmic composition comprising: an effective amount of an isoxazoline parasiticide, wherein the isoxazoline parasiticide is present at between about 0.10% and about 0.50% by weight with respect to the total weight of the composition; a hydrogenated castor oil; a polysaccharide thickener; and glycerin, wherein the glycerin is present at between about 0.5% and about 4% by weight with respect to the total weight of the composition. 2. The ophthalmic composition of claim 1, wherein the ophthalmic composition is in eye drop form. 3. The ophthalmic composition of claim 1, wherein the combination of the hydrogenated castor oil and the polysaccharide thickener forms a long-lasting film layer. 4. The ophthalmic composition of claim 1, wherein the ophthalmic composition is characterized by a viscosity, wherein the viscosity is sufficiently high to cause the ophthalmic composition to spread over meibomian gland orifices on upper and/or lower lid margins upon blinking or closing of the eye and to slow evacuation of the ophthalmic composition through the puncta of the eye for at least 20 seconds. 5. The ophthalmic composition of claim 1, wherein the isoxazoline parasiticide comprises lotilaner. 6. The ophthalmic composition of claim 1, wherein the isoxazoline parasiticide is present at about 0.25% by weight with respect to the total weight of the composition. 7. The ophthalmic composition of claim 1, wherein the hydrogenated castor oil comprises polyoxyl 35 castor oil. 8. The ophthalmic composition of claim 1, wherein the hydrogenated castor oil is present at about 5% by weight with respect to the total weight of the composition. 9. The ophthalmic composition of claim 1, wherein the polysaccharide thickener comprises hydroxypropyl methylcellulose. 10. The ophthalmic composition of claim 1, wherein the polysaccharide thickener comprises carboxymethyl cellulose. 11. The ophthalmic composition of claim 1, wherein the polysaccharide thickener is present at between about 0.1% and about 0.5% by weight with respect to the total weight of the composition. 12. The ophthalmic composition of claim 1, wherein the polysaccharide thickener is present at about 0.2% by weight with respect to the total weight of the composition. 13. The ophthalmic composition of claim 1, further comprising a preservative agent, wherein the preservative agent comprises potassium sorbate. 14. The ophthalmic composition of claim 13, wherein the preservative agent does not comprise lauralkonium chloride or benzalkonium chloride. 15. The ophthalmic composition of claim 1, further comprising a preservative agent, wherein the preservative agent comprises lauralkonium chloride. 16. The ophthalmic composition of claim 1, further comprising a preservative agent, wherein the preservative agent comprises benzalkonium chloride. 17. The ophthalmic composition of claim 1, further comprising a preservative agent, wherein the preservative agent is present at between about 0.15% and about 0.4% by weight with respect to the total weight of the composition. 18. The ophthalmic composition of claim 1, wherein the ophthalmic composition does not comprise tea tree oil. 19. The ophthalmic composition of claim 1, wherein the isoxazoline parasiticide is the sole active ingredient of the ophthalmic composition. 20. The ophthalmic composition of claim 1, wherein the ophthalmic composition is only locally therapeutically effective. 21. The ophthalmic composition of claim 1, wherein the ophthalmic composition is formulated as a gel.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.